See the DrugPatentWatch profile for Ezetimibe
Ezetimibe, a cholesterol-lowering medication, received its initial approval from the U.S. Food and Drug Administration (FDA) on October 27, 2002 [1]. It is marketed under the brand name Zetia [1].
When does Ezetimibe's market exclusivity expire?
The patent protection and market exclusivity for Ezetimibe have been subject to various legal challenges and extensions over the years. Information regarding specific patent expiry dates and the status of exclusivity can be found through specialized resources like DrugPatentWatch.com [2].
What are the different ways Ezetimibe can be taken?
Ezetimibe is typically administered orally as a single agent or in combination with statins [1]. Combination products, such as ezetimibe-simvastatin (Vytorin), have also been approved [3].
What clinical data supports Ezetimibe's effectiveness?
Clinical trials have demonstrated that Ezetimibe effectively lowers low-density lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol [1]. It works by inhibiting the absorption of cholesterol in the small intestine [1]. Studies have shown that Ezetimibe, when used alone or with a statin, leads to significant reductions in LDL-C levels [1].
Are there any safety concerns or side effects associated with Ezetimibe?
Commonly reported side effects of Ezetimibe include diarrhea, fatigue, headache, and muscle pain [1]. More serious but less common side effects can include liver problems and rhabdomyolysis, particularly when Ezetimibe is combined with statins [1].
What are the alternatives to Ezetimibe for cholesterol management?
Besides Ezetimibe, other classes of cholesterol-lowering medications are available. Statins are a primary treatment option and work by reducing cholesterol production in the liver [4]. Other alternatives include PCSK9 inhibitors, bile acid sequestrants, and fibrates, each with different mechanisms of action and efficacy profiles [4].
How does Ezetimibe compare to statins?
Ezetimibe and statins differ in their mechanisms of action. Statins reduce the liver's production of cholesterol, while Ezetimibe inhibits the absorption of cholesterol from the diet and bile in the small intestine [1, 4]. Ezetimibe is often used as an add-on therapy for patients who cannot reach their LDL-C goals with statins alone or for those who cannot tolerate statins [1].
What is the typical cost of Ezetimibe?
The cost of Ezetimibe can vary depending on factors such as insurance coverage, pharmacy, and dosage. Both brand-name Zetia and its generic versions are available.
Are there generic versions of Ezetimibe available?
Yes, generic versions of Ezetimibe have become available, which generally leads to lower prices compared to the brand-name product [2].
What is the mechanism of action for Ezetimibe?
Ezetimibe targets Niemann-Pick C1-Like 1 (NPC1L1) protein located on the brush border of enterocytes in the small intestine. By inhibiting this protein, Ezetimibe blocks the absorption of dietary and biliary cholesterol, leading to reduced delivery of cholesterol to the liver [1].
When did Ezetimibe become available in other countries?
While Ezetimibe was first approved in the U.S. in 2002, its approval dates in other countries may vary. For specific international approval timelines and market entry dates, resources detailing global pharmaceutical approvals would be necessary.
Sources:
1. https://www.accessdata.fda.gov/drugsatfdadocs/label/2004/021226lbl.pdf
2. https://drugpatentwatch.com/
3. https://www.accessdata.fda.gov/drugsatfdadocs/label/2007/021833s005lbl.pdf
4. https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/cholesterol/art-20045191